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Objective: The goal of this study is to evaluate pulmonary function and respiratory center
drive in patients with early-stage idiopathic Parkinson’s disease (IPD) to facilitate early
diagnosis of Parkinson’s Disease (PD).
Methods: 43 IPD patients (Hoehn and Yahr scale of 1) and 41 matched healthy
individuals (e.g., age, sex, height, weight, BMI) were enrolled in this study. Motor
status was evaluated using the Movement Disorders Society-Unified PD Rating Scale
(MDS-UPDRS). Pulmonary function and respiratory center drive were measured using
pulmonary function tests (PFT). All IPD patients were also subjected to a series of
neuropsychological tests, including Non-Motor Symptoms Questionnaire (NMSQ), REM
Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Beck Depression Inventory
(BDI) and Mini Mental State Examination (MMSE).
Results: IPD patients and healthy individuals have similar forced vital capacity (FVC),
forced expiratory volume in 1s (FEV1), forced expiratory volume in 1s/forced vital
capacity (FEV1/FVC), peak expiratory flow (PEF), and carbonmonoxide diffusion capacity
(DLCOcSB). Reduced respiratory muscle strength, maximal inspiratory pressure (PImax)
and maximal expiratory pressure (PEmax) was seen in IPD patients (p = 0.000 and
p = 0.002, respectively). Importantly, the airway occlusion pressure after 0.1 s (P0.1)
and respiratory center output were notably higher in IPD patients (p = 0.000) with a
remarkable separation of measured values compared to healthy controls.
Conclusion: Our findings suggest that abnormal pulmonary function is present in early
stage IPD patients as evidenced by significant changes in PImax, PEmax, and P0.1.
Most importantly, P0.1 may have the potential to assist with the identification of IPD in
the early stage.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common chronic
and progressive neurodegenerative disease in the elderly (1).
Although the pathogenesis of PD has been redefined with
triggers (e.g., viral infections or environmental toxins),
facilitators (e.g., systemic inflammation, mitochondrial
dysfunction, and genetic facilitators), and aggravators (e.g.,
impaired autophagy, neuroinflammation), there is a complex
interplay of genetic, aging, and environmental factors that
result in PD (2). Consequently, clinical challenges remain
because it is difficult to provide a definitive diagnosis at the
earliest stage. This has led to an urgent yet unmet need to
find a useful examination to facilitate the early diagnosis of
PD (3).
Pulmonary function impairment has been studied in
idiopathic Parkinson’s disease (IPD), the most common type of
Parkinsonism whereby the cause is unknown (4). Pulmonary
dysfunction has been known as an autonomic disorder equated
to non-motor symptoms of PD in several studies. Abnormalities
involving obstructive, restrictive and mixed-type pulmonary
dysfunction increases disability in PD patients (5). Moreover,
respiratory complications, such as aspiration pneumonia and
pulmonary embolism are associated with mortality of PD
patients (6). A systematic review and meta-analysis suggested
asymptomatic respiratory impairment can be discovered even
in the initial stages of the disease course (7). In the past
decades, research on PD and lung function has brought some
meaningful discoveries. Based on the experimental designs
and conclusions, these studies can be classified into four main
topics: first is the effect of Levodopa (combined with different
formulation) on pulmonary dysfunction in PD; the second
is about dysregulated lung function, especially ventilatory
dysfunction, diffusion impairment, obstructive, and restrictive
disorders in PD; the third is the potential relationship between
swallowing impairment and respiratory dysfunction in PD;
the last is the therapeutic effect of rehabilitation (e.g., YOGA,
Qigong) on pulmonary function in patients with PD (8–12). It
is worth mentioning that most of these studies were performed
in patients in the advanced stage of PD. Currently, whether
pulmonary function is affected in early stage IPD patients
remains elusive.
As a valid measurement of respiratory center drive, the
airway occlusion pressure (P0.1) is a simple, convenient, non-
invasive measurement index. It is described as the pressure
developed in the occluded airway 100ms after the onset of
inspiration (13). P0.1 is commonly monitored in respiratory
diseases, along with respiratory failure and chronic obstructive
pulmonary disease (COPD). It is a sensitive indicator of
respiratory drive to predict extubation failure in ICU (14).
However, respiratory center drive in early IPD has never
been studied.
In the present study, we therefore evaluated respiratory
center drive and pulmonary function in early-stage IPD patients.
Specifically, we examined the pulmonary ventilation function,
respiratory muscle strength index, and respiratory drive in early
IPD patients and healthy controls.
SUBJECTS/MATERIALS AND METHODS
Human Subjects
In this study, a total of 43 IPD patients (19 male, 24 female;
mean age 62.60± 6.60 years) and 41 healthy control subjects (21
male, 20 female; mean age 61.39± 5.87 years) were enrolled from
May 2017 to September 2018 at the Department of Neurology
at the General Hospital, Tianjin Medical University, Tianjin,
China. The main clinical characteristics of the study population
are summarized in Table 1. There were no significant differences
in the age, height, weight, and BMI between IPD patients
and healthy controls (Table 2). All IPD patients have a mean
disease duration of 1.67 ± 1.14 years and received regular
dopaminergic treatment with a mean total levodopa equivalent
dose (LED) 313.18 ± 206.50mg according to conversion
factors among dopamine drugs recommended by the Movement
Disorder Society (15). All subjects signed written informed
consent before being recruited for the study. The study was
approved and performed in accordance with the guidelines
of the Ethics Committee of the General Hospital of Tianjin
Medical University.
Inclusion Criteria of the PD Patients
All patients were diagnosed with IPD based on the clinical criteria
of the United Kingdom PD Society Brain Bank (16). Motor
status was evaluated using the Movement Disorders Society-
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The
Hoehn and Yahr stages of all patients were 1 (H&Y stage =
1), clinical signs and symptoms were unilateral involved only,
usually with minimal or no functional impairment (17), and
all these PD patients had no fluctuations in symptoms, such as
on-off phenomena.
Exclusion Criteria of the PD Patients
IPD patients were excluded under the following conditions:
(1) Suffering from any clinical neurological, respiratory,
cardiovascular, or other systemic diseases verified by specialized
physicians through clinical and appropriate instrumental
diagnosis, such as cerebral infarction, cerebral hemorrhage,
encephalitis, Myasthenia Gravis, COPD, asthma, emphysema,
respiratory tract infection, anemia, coronary heart disease
etc.; (2) Complaining of any heart and lung discomfort (e.g.,
dyspnea, palpitation, etc.); (3) History of smoking or lung, brain
or cardiac surgery trauma; (4) Receiving any treatments (e.g.,
β-blocker, sedatives, hypnotics, antibiotic, NAIDS, etc.) that may
influence pulmonary function; (5) Severe cognitive dysfunction
or dementia according to the Mini-Mental State Examination
(MMSE < 25) (18); (6) Other causes leading to the inability to
tolerate the study or factors affecting lung function.
Requirements for Healthy Subjects
The healthy controls were age, sex, and BMI matched with all
PD patients. They were in healthy condition at the time of the
study and were screened for the same exclusion criteria as the
PD patients.
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TABLE 1 | Overview of the demographic and clinical characteristics of PD patients and healthy controls.
PD patients Healthy controls
Case# Age (years,
range)
Diagnosis Disease duration
(years)
Hoehn and
Yahr scale
Levodopa
equivalent doses
(LED, mg)
Case# Age (years,
range)
1 50–60 IPD 1 1 50.00 1 60–70
2 60–70 IPD 2 1 575.00 2 60–70
3 60–70 IPD 1 1 375.00 3 70–80
4 50–60 IPD 2 1 100.00 4 60–70
5 50–60 IPD 2 1 531.95 5 60–70
6 60–70 IPD 1 1 190.98 6 70–80
7 60–70 IPD 0.5 1 525.00 7 60–70
8 60–70 IPD 4 1 350.00 8 60–70
9 60–70 IPD 2 1 525.00 9 60–70
10 50–60 IPD 2 1 50.00 10 60–70
11 60–70 IPD 3 1 237.50 11 60–70
12 60–70 IPD 1 1 437.50 12 60–70
13 60–70 IPD 2 1 250.00 13 60–70
14 70–80 IPD 1 1 375.00 14 60–70
15 50–60 IPD 1 1 50.00 15 60–70
16 50–60 IPD 1 1 250.00 16 60–70
17 50–60 IPD 2 1 237.50 17 60–70
18 60–70 IPD 1 1 187.50 18 60–70
19 70–80 IPD 1 1 400.00 19 50–60
20 70–80 IPD 1 1 412.50 20 60–70
21 50–60 IPD 0.5 1 87.50 21 60–70
22 60–70 IPD 1 1 50.00 22 50–60
23 50–60 IPD 2 1 287.50 23 60–70
24 60–70 IPD 3 1 575.00 24 50–60
25 60–70 IPD 1 1 350.00 25 50–60
26 60–70 IPD 0.5 1 375.00 26 50–60
27 60–70 IPD 3 1 312.50 27 50–60
28 50–60 IPD 1 1 50.00 28 60–70
29 40–50 IPD 2 1 75.00 29 40–50
30 60–70 IPD 2 1 768.75 30 50–60
31 60–70 IPD 0.5 1 50.00 31 50–60
32 60–70 IPD 4 1 550.00 32 50–60
33 60–70 IPD 5 1 725.00 33 60–70
34 50–60 IPD 2 1 375.00 34 50–60
35 60–70 IPD 1 1 750.00 35 60–70
36 60–70 IPD 1 1 412.50 36 50–60
37 70–80 IPD 5 1 525.00 37 50–60
38 50–60 IPD 1 1 287.50 38 60–70
39 60–70 IPD 1 1 50.00 39 50–60
40 70–80 IPD 1 1 87.50 40 60–70
41 60–70 IPD 1 1 375.00 41 50–60
42 60–70 IPD 1 1 187.50
43 60–70 IPD 1 1 50.00
As illustrated in Table 1, 43 idiopathic Parkinson’s disease (IPD) patients (19 male and 24 female) with Hoehn and Yahr scale of 1 and 41 healthy controls (21 male and 20 female)
enrolled in this study.
Instruments and Procedures
All the patients and healthy controls underwent pulmonary
function tests (PFT) according to the standards set by the
American Thoracic Society (ATS) under the guidance of a
respiratory physician. The apparatus used in this study included
a spirometer and a respiratory actuator (MasterScreen, JAEGER,
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TABLE 2 | Demographic and clinical data of PD patients and healthy controls and
NPF group.
PD (N = 43) Healthy controls (N = 41) p
Gender (male/female) 19/24 21/20 0.519
Age (years) 62.60 ± 6.60 61.39 ± 5.87 0.376
Height (m) 1.62 ± 0.07 1.65 ± 0.08 0.060
Weight (kg) 64.81 ± 10.72 66.15 ± 11.85 0.591
BMI 24.67 ± 3.32 24.23 ± 3.32 0.567
Disease duration (years) 1.67 ± 1.14 NA NA
MDS-UPDRS 15.58 ± 5.95 NA NA
NMSQ 7.37 ± 3.89 NA NA
RBDSQ 2.88 ± 3.16 NA NA
BDI 7.16 ± 8.08 NA NA
MMSE 28.11 ± 1.82 NA NA
As illustrated in Table 2, the PD group and healthy control (HC) group had similar
mean ages, gender, height, weight, and Body Mass Index (BMI) (all p > 0.05). MDS-
UPDRS, Movement Disorder Society—Unified Parkinson’s Disease Rating Scale; NMSQ,
non-motor symptoms questionnaire; RBDSQ, REM Sleep Behavior Disorder Screening
Questionnaire; BDI, Beck Depression Inventory; MMSE, Mini-Mental State Examination.
Germany). To ensure research consistency, fixed check time
(8:00–12:00 a.m.), place (in a quiet environment, reducing the
impact on subjects), and indoor temperature (24–28◦C) were
kept constant. Before the test, these early-stage PD patients
were required to stop the associated anti-Parkinson’s disease
treatment at least 12 h to avoid the impact of drugs on testing.
Beyond that, all patients underwent related neuropsychological
assessments. Parameters related to PFT and various symptom
scales are as follows:
Parameters Related to PFT
Predicted values were automatically generated by the PFT
equipment according to the height, weight and age of
the examinees before the test. Following examination, the
percentages of the measured value from the test compared to the
predicted value from the computer were automatically calculated.
In this study, these percentages were considered as the PFT
measurements to be recorded and processed further.
Ventilation Function Indicators
The percentages of the predicted values of forced vital
capacity (FVC%), forced expiratory volume in 1s (FEV1%),
forced expiratory volume in 1s/forced vital capacity
(FEV1/FVC%), peak expiratory flow (PEF%), total lung
capacity (TLC%), residual volume (RV%), carbon monoxide
diffusion capacity (DLCOcSB%) were evaluated as indicators of
ventilation function.
Respiratory Muscle Strength Index
The percentages of the predicted values of maximal inspiratory
pressure (PImax%) and maximal expiratory pressure (PEmax%)
were measured to determine the respiratory muscle strength.
Respiratory Drive Index
The percentage of the predicted value of the airway
occlusion pressure (P0.1%) was examined to determine the
respiratory drive.
Neuropsychological Examination
To assess neuropsychological status, all patients also underwent
the Non-Motor Symptoms Questionnaire (NMSQ), REM
sleep behavior Disorder Screening Questionnaire (RBDSQ),
Beck Depression Inventory (BDI), and Mini Mental State
Examination (MMSE).
Statistical Analysis
Statistical analyses were performed using SPSS 22.0 (IBM,
USA). All the summary results were presented as the mean
± standard deviation (SD). All data was first checked for any
potential outliers and tested for normality using the Shapiro-Wilk
normality test. Data Significance was then assessed by student’s
unpaired t-test for data with normal distributions. A value of p <
0.05 was considered to be statistically significant.
RESULTS
Unaltered Pulmonary Ventilation Function
in Early-Stage IPD Patients
We first assessed the pulmonary ventilation function in early-
stage IPD patients and healthy controls by measuring FVC
(%), FEV1 (%), FVC/FEVF1 (%), PEF (%), RV (%), TLC (%),
and DLCOcSB (%) (Figure 1). Consistent with the early clinical
stage of these IPD patients, we found no significant changes in
ventilation function in IPD patients (FVC: 105.51 ± 17.24%;
FEV1: 102.67 ± 18.50%; FVC/FEVF1: 79.27 ± 9.46%; PEF:
103.19 ± 20.67%; RV: 94.26 ± 17.09%; TLC: 92.04 ± 9.67%;
DLCOcSB: 83.57± 15.55%; n= 43) compared to healthy controls
(FVC: 104.38 ± 15.90%, p = 0.76; FEV1: 102.12 ± 13.93%, p
= 0.88; FVC/FEVF1: 79.71 ± 6.10%, p = 0.80; PEF: 109.01 ±
13.99%, p = 0.13; RV: 97.64 ± 16.65%, p = 0.36; TLC: 93.21 ±
11.26 %, p = 0.61; DLCOcSB: 88.63 ± 14.09%, p = 0.12; n =
41). In addition, there were no significant correlations between
pulmonary ventilation function tests and neuropsychological
assessments (p > 0.05, Table 3).
Decreased Respiratory Muscle Strength in
Early-Stage IPD Patients
We next evaluated respiratory muscle strength by assessing
muscle strength index PImax and PEmax in both early-stage
IPD patients and healthy controls. As shown Figures 2A,D, the
early-stage IPD patients showed a significant reduction in both
PImax (38.82 ± 16.87%, n = 43) and PEmax (68.13 ± 20.31%,
n = 43) compared to healthy controls (PImax: 53.17 ± 16.00%,
n = 41, p = 0.001; PEmax: 87.49 ± 32.46%, n = 41, p =
0.002). No significant correlations were found between PImax
and neuropsychological assessments (MDS-UPDRS: p = 0.08, r
= −0.02; NMSQ: p = 0.97, r = −0.01; RBDSQ: p = 0.70, r =
0.06; BDI: p= 0.99, r= 0.00; MMSE: p= 0.27, r= 0.17; Table 3),
or between PEmax and neuropsychological assessments (MDS-
UPDRS: p= 0.43, r=−0.12; NMSQ: p= 0.42, r= 0.13; RBDSQ:
p = 0.52, r = 0.10; BDI: p = 0.45, r = −0.12; MMSE: p = 0.84,
r = 0.03; Table 3). To further determine whether there is any
sex-specific difference, we performed subgroup analysis by sex
(Figures 2B,C,E,F). We found that both female and male early-
stage IPD patients show a significant decrease in PImax (Female
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FIGURE 1 | Comparisons of the pulmonary ventilation function between early-stage PD patients and age-matched healthy controls. (A–G) Percentage of predicted
values of FVC (A), FEV1 (B), FEV1/FVC (C), DLCOc SB (D), FEF (E), RV-SB (F), and TLC-SB (G) showed no significant difference between early-stage PD patients
(open circles, n = 43) and age-matched healthy controls (filled circles, n = 41, p > 0.05). Each symbol represents a single subject. Data are presented as mean ± SD.
PD patients: 34.82 ± 16.39%, n = 24; Male PD patients: 43.87 ±
16.52%, n = 19, Figures 2B,C) and PEmax (Female PD patients:
71.60 ± 22.39%, n = 24; Male PD patients: 63.73 ± 16.91%, n =
19, Figures 2E,F) compared to female (PImax: 50.15± 14.73%, n
= 20, p= 0.0024; PEmax: 98.16± 37.77%, n= 20, p= 0.006) and
male (PImax: 56.06 ± 16.98%, n = 21, p = 0.027; PEmax: 77.33
± 23.02%, n= 21, p= 0.042) healthy controls.
Increased Respiratory Drive in Early-Stage
IPD Patients
Respiratory center drive, P0.1, is associated with the level of
muscular inspiratory activity. As we found significant decreases
in respiratory muscle strength, we next aimed to assess
respiratory center drive in early-stage IPD patients as well
as healthy controls (Figure 3). Indeed, we found that early-
stage IPD patients showed significant increases in respiratory
center drive P0.1 (156.78 ± 63.24%, n = 43) compared to
age-matched controls (82.40 ± 13.14%, n = 41, p < 0.001,
Figure 3A). Importantly, both female and male early-stage
IPD patients show a significant increase in P0.1 (Female PD
patients: 181.1 ± 73.00%, n = 24; Male PD patients: 126.1 ±
27.31%, n = 19, Figures 3B,C) compared to female (85.70 ±
10.78%, n = 20, p = 0.001) and male (79.26 ± 14.61%, n =
21, p = 0.001) healthy controls. It is worth mentioning that
respiratory center drive P0.1 values of most male and female IPD
patients were indeed separated from control values with minimal
overlap. No significant correlations were found between P0.1 and
neuropsychological assessments (MDS-UPDRS: p = 0.45, r =
0.12; NMSQ: p = 0.63, r = −0.08; RBDSQ: p = 0.53, r = −0.10;
BDI: p= 0.33, r =−0.15; MMSE: p= 0.59, r = 0.88; Table 3).
DISCUSSION
The present study provides the first evidence of abnormal
pulmonary function in the very early stage of IPD. As
documented here, patients with early IPD had significantly lower
respiratory muscle strength (PImax%, PEmax%) and higher
central respiratory drive (P0.1%) than those in age-matched
healthy controls. Importantly, the values of measured respiratory
center drive P0.1 showed a remarkable separation between the
early-stage IPD patients and healthy controls, indicating its
potential utility for diagnosis of the early-stage IPD patients.
Abnormalities of peak expiratory and inspiratory flows
(PEF, PIF) were found in patients with relatively severe PD and
without clinical signs or symptoms of respiratory problem. These
changes can be explained by “muscle weakness” and hypokinesia,
two symptoms intrinsic to PD (19). What’s more, levodopa
improved significant variations in PEF by decreasing tremor
and muscle rigidity, increasing coordination of muscles, and
facilitating movement (20). In previous studies, upper airway
dysfunction and a restrictive pattern are the main spirometric
findings in PD. The main reasons might be a poor coordination
or rigidity of respiratory muscles, which could limit forced
respiratory movements (21). Unlike many previous studies,
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TABLE 3 | Correlation analysis of pulmonary function tests (PFT) values and
neuropsychological assessments.
MDS-UPDRS NMSQ RBDSQ BDI MMSE
FVC (%) r −0.04 0.13 −0.04 0.02 −0.08
P 0.81 0.40 0.83 0.15 0.61
FEV1 (%) r −0.20 0.17 0.05 0.12 0.07
P 0.20 0.27 0.74 0.44 0.68
FVC/FEV1(%) r −0.27 0.10 0.15 −0.23 0.07
P 0.08 0.51 0.33 0.15 0.68
PEF (%) r −0.23 −0.00 0.00 0.03 0.35
P 0.13 0.99 0.99 0.86 0.06
RV (%) r −0.22 −0.24 −0.18 −0.19 −0.04
P 0.15 0.12 0.24 0.21 0.79
TLC (%) r −0.25 −0.09 −0.04 0.13 −0.07
P 0.11 0.59 0.82 0.41 0.66
DLCOcSB(%) r −0.16 −0.01 −0.11 −0.21 0.08
P 0.32 0.93 0.49 0.18 0.63
PImax (%) r −0.02 −0.01 0.06 0.00 0.17
P 0.88 0.97 0.70 0.99 0.27
PEmax (%) r −0.12 0.13 0.10 −0.12 0.03
P 0.43 0.42 0.52 0.45 0.84
P0.1 (%) r 0.12 −0.08 −0.10 −0.15 0.88
P 0.45 0.63 0.53 0.33 0.59
As illustrated in Table 3, there was no significant correlation between pulmonary function
tests values and neuropsychological assessments.
our data did not show any respiratory abnormalities including
ventilation or diffusion dysfunction. This may be because the
subjects in our study were very early stage patients (H&Y scale of
1) rather than more severe patients (H&Y scale of 2 or higher).
Respiratory muscle strength, assessed by measuring the maximal
inspiratory and expiratory mouth pressures (PImax and PEmax)
was decreased in IPD patients. Furthermore, all these parameters
of respiratory muscle performance tended to increase in the
“on” period rather than the “off” period, although this increase
did not reach statistical significance (22). This was due to poor
posture restricting chest and abdominal movements, rigidity
resulting in poor chest wall compliance and disrupted respiratory
muscle coordination (23). Consistent with previous studies, our
findings that the values of PImax and PEmax in early-stage
IPD were significantly lower than the healthy controls suggest
that inspiratory muscle strength appears to be impaired in IPD
patients at very early stage (24). As previously thought, PD
involves dysfunction in both movement and muscle tone in
the trunk and limbs related to abnormal thoracoabdominal
movements as well as incoordination of respiratory
muscle (25).
Respiratory center drive, or P0.1, is associated with the level
of muscular inspiratory activity. It involves the nerve impulse
that the respiratory center gives out to stimulate the inspiratory
muscle to contract when we inhale. It is mainly affected by
sensitivity of chemoreceptors in vivo, partial pressure of arterial
oxygen CO2, resistance to inhalation, and abnormal function of
inspiratory muscles (26). The output of the respiratory center
can be estimated by many parameters, such as ventilation,
inspiratory muscle power or EMG of the diaphragm. However,
P0.1, the airway occlusion pressure (the negative airway pressure
generated during the first 100ms of an occluded inspiration)
represents the most important index of the output of the
respiratory centers (27). In many studies, P0.1 is a useful
parameter in setting the level of pressure support ventilation
in mechanical ventilation (28). Additionally, P0.1 can be used
as a good indicator of postextubation respiratory distress after
extubation (29). The most striking finding of our study was
significant changes in respiratory center drive in patients with
early stage IPD. The percentage of the predicted values of
P0.1 (P0.1%) in IPD group was significantly higher than in
the control group (p < 0.001). In our study, factors such
as respiratory diseases or smoking which can influence P0.1
were excluded, suggesting that the abnormal respiratory drive
was, therefore, mainly related to IPD itself. Based on relevant
literature, there are two possible mechanisms at play. First is
abnormal respiratory muscle strength of PD patients (peripheral
mechanisms). Second is abnormalities in the respiratory center
itself (central mechanisms). Abnormalities of the chest wall or
its musculature can change lung volumes without necessarily
altering expiratory flow (30). PD with a restrictive pattern
of pulmonary dysfunction could probably be explained by
abnormally low chest wall compliance secondary to chest wall
rigidity (31). As described in the diagnostic criteria, as PD
patients manifest their core symptoms, such as rigidity and
bradykinesia, their movements become slow, clumsy, inflexible
and uncoordinated, which impairs the tone, contractility, and
coordination of thoracic musculature. As a result, the respiratory
mechanics and pulmonary function are affected. The decrease of
respiratory muscle force may cause an increase in compensation
of central respiratory driving force to maintain adequate
physiological ventilation. This central self-regulation mechanism
is common in respiratory diseases such as COPD and asthma
(32). In our study, the H&Y scale of IPD patients is 1 (the
course of illness is extremely short), so the impairment of
common lung ventilation (restrictive, obstructive, and mixed),
is not evident or within the scope of compensation. So, P0.1
is a useful and sensitive measurement in early-stage IPD (28).
Another mechanism involved is the problem with the respiratory
center itself. Based on the Braak hypothesis, which suggests
that alpha-synuclein aggregation starts from olfactory bulb and
dorsal vagus nucleus, and develops gradually up and forward
along the brain stem, there is early brainstem involvement
in PD patients (33). Some researchers suggest that there is
a depletion of the chemosensitive glutamatergic neurons in
the dorsolateral pons and the ventrolateral medulla in both
PD and MSA patients, which may trigger the impairment
of respiratory muscle control (34). In a recent study by Lee
et al. involvement of the central autonomic network and
gray matter loss may underlie the respiratory dysfunction in
PD patients (35). In addition, autonomic nerve dysfunction,
such as vagus nerve damage, leads to increased upper airway
muscle tone, resulting in uncoordinated local movements
and weak muscular contraction (36, 37). There is currently
little evidence of brainstem-mediated respiratory dysfunction,
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FIGURE 2 | Comparisons of the respiratory muscle strength between early-stage PD patients and age-matched healthy controls. (A–C) Percentage of predicted
values of maximal inspiratory pressure [PImax, (A)] was significantly lower in early-stage PD patients (open circles, n = 43) and age-matched healthy controls (filled
circles, n = 41, **p < 0.001). Note that both female [(B), n = 24] and male [(C), n = 19] early-stage PD patients (open circles) showed significantly lower values of
PImax compared to the corresponding healthy controls (filled circles; female n = 20, male n = 21, *p < 0.05, **p < 0.01). (D–F) Percentage of predicted values of
maximal expiratory pressure [PEmax, (D)] was significantly lower in early-stage PD patients (open circles, n = 43) and age-matched healthy controls (filled circles, n =
41, **p < 0.001). Note that both female [(E), n = 24) and male [(F), n = 19] early-stage PD patients (open circles) showed significantly lower values of PEmax
compared to the corresponding healthy controls (filled circles; female n = 20, male n = 21, *p < 0.05, **p < 0.01). Each symbol represents a single subject. Data are
presented as mean ± SD.
FIGURE 3 | Comparisons of the respiratory drive between early-stage PD patients and age-matched healthy controls. (A) Percentage of predicted values of
respiratory center drive (P0.1), was significantly higher in early-stage PD patients (open circles, n = 43) and age-matched healthy controls (filled circles, n = 41, **p <
0.001). (B–C) Both female [(B), n = 24] and male [(C), n = 19] early-stage PD patients (open circles) showed significantly larger values of PImax compared to the
corresponding female [(B), n = 20] and male [(C), n = 21] healthy controls (filled circles, **p < 0.01). Each symbol represents a single subject. Data are presented as
mean ± SD.
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however it seems reasonable that as PD progresses along
with further loss of dopaminergic cells in the midbrain, basal
ganglia and medulla, respiratory function and ventilation will
deteriorate (38).
The early diagnosis of PD will greatly help optimize
therapeutic strategies, especially in cases with very mild or a-
typical motor and non-motor symptoms. That being said, we
have found significant increases in respiratory center drive (P0.1)
and decreases in respiratory muscle strength PImax and PEmax
in early-stage IPD patients. Importantly, measured P0.1 values in
both female and male early-stage IPD patients were remarkably
separated from those in healthy controls, while measured PImax
and PEmax values showed moderate overlap between early-
stage IPD patients and healthy controls. Therefore, our data
strongly supports P0.1 as a safe, non-invasive and convenient
measurement for early-stage IPD in clinical practice.
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